

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of groups n = 5

EQA round: AKS3/17 - Basic Clinical Chemistry - Serum

Dead line: 28.07.2017

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Traceability																		
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}											
(1) Sodium					22							0			22	22	100%								
Samples and groups	[mmol/L]																								
Sample A		131	2,6	2,0	22							0	CRV	130,7	2,0	5%	124	138	22	22	100%				
(2) Indirect ISE		131	2,2	1,7	20	0													20						
Other					2	0														2					
													1x 3, 1x 99												
Sample B		139	2,1	1,5	22							0	CRV	139,1	2,1	5%	132	147	22	22	100%				
(2) Indirect ISE		139	2,2	1,5	20	0														20					
Other					2	0															2				
														1x 3, 1x 99											
(2) Potassium					22							0								22	21	95%			
Samples and groups	[mmol/L]																								
Sample A		6,74	0,23	3,4	22							0	CRV	6,766	0,10	8%	6,22	7,31	22	21	95%				
(2) Indirect ISE		6,77	0,19	2,9	20	0														20					
Other					2	0															2				
														1x 3, 1x 99											
Sample B		3,93	0,08	2,3	22							0	CRV	3,876	0,058	8%	3,56	4,19	22	22	100%				
(2) Indirect ISE		3,94	0,08	2,1	20	0														20					
Other					2	0															2				
														1x 3, 1x 99											
(3) Chloride					22							22	21	95%						0					
Samples and groups	[mmol/L]																								
Sample A		112	2,4	2,2	22	CVP	113	0,65	7%	105	121	22	21	95%						0					
(3) Indirect ISE		112	2,5	2,3	19	0						19													
Other					3	0						3													
							2x 2, 1x 4																		
Sample B		122	2,2	1,8	22	CVP	123	0,76	7%	114	132	22	21	95%						0					
(3) Indirect ISE		122	2,4	1,9	19	0						19													
Other					3	0						3													
							2x 2, 1x 4																		
(4) Calcium					21							0								21	21	100%			
Samples and groups	[mmol/L]																								
Sample A		2,61	0,08	3,3	21							0	CRV	2,605	0,039	10%	2,34	2,87	21	21	100%				
(3) Phatom. with arsenazo III		2,58	0,11	4,1	12	0															12				
(4) Complex Ca-NM-BAPTA		2,63	0,03	1,1	5	0															5				
Other					4	0																4			
														4x 2											
Sample B		3,04	0,06	2,2	21							0	CRV	3,02	0,045	10%	2,71	3,33	21	21	100%				
(3) Phatom. with arsenazo III		3,02	0,08	2,9	12	0															12				
(4) Complex Ca-NM-BAPTA		3,04	0,02	0,73	5	0															5				
Other					4	0																4			
														4x 2											

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of groups n = 5

EQA round: AKS3/17 - Basic Clinical Chemistry - Serum

Dead line: 28.07.2017

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(5) Inorganic phosphate					20							20	20	100%							0		
Samples and groups	[mmol/L]																						
Sample A		1,70	0,03	2,0	20	CRV	1,7	0,013	10%	1,53	1,87	20	20	100%							0		
(1) UV-molybdate method		1,70	0,03	1,9	19							19											
Other					1							1											
Sample B		1,97	0,03	1,5	20	^{1x2} CVP	1,97	0,013	10%	1,77	2,17	20	20	100%							0		
(1) UV-molybdate method		1,97	0,02	1,4	19							19											
Other					1							1											
(6) Iron					20							20	20	100%							0		
Samples and groups	[µmol/L]																						
Sample A		23,2	0,94	4,0	20	CVP	23,1	0,22	15%	19,6	26,6	20	20	100%							0		
(2) Method with ferrozine/ferene		23,9	1,2	5,0	11							11											
(4) Method with TPTZ		22,7	0,44	2,0	9							9											
Sample B		29,5	0,96	3,3	20	CVP	29,5	0,23	15%	25	34	20	20	100%							0		
(2) Method with ferrozine/ferene		30,1	0,73	2,4	11							11											
(4) Method with TPTZ		28,8	0,62	2,1	9							9											
(7) Magnesium					21							0									21	20	95%
Samples and groups	[mmol/L]																						
Sample A		1,48	0,05	3,5	21							0		CRV	1,479	0,022	15%	1,25	1,71	21	20	95%	
(2) Photometry		1,48	0,05	3,6	20							0									20		
Other					1							1									1		
Sample B		1,96	0,07	3,8	21							0		^{1x4} CRV	1,97	0,030	15%	1,67	2,27	21	21	100%	
(2) Photometry		1,96	0,07	4,0	20							0									20		
Other					1							1									1		
(8) Lithium					5							0									5	5	100%
Samples and groups	[mmol/L]																						
Sample A		1,20	0,03	3,3	5							0		CRV	1,238	0,020	12%	1,08	1,39	5	5	100%	
Other					5							0									5		
Sample B		1,81	0,07	4,1	5							0		^{1x3,4x4} CRV	1,853	0,028	12%	1,63	2,08	5	5	100%	
Other					5							0									5		
(9) Total protein					23							0									23	23	100%
Samples and groups	[g/L]																						
Sample A		56,2	1,5	2,6	23							0		CRV	56,54	1,2	9%	51,4	61,7	23	23	100%	
(1) Biuret		56,2	1,5	2,6	23							0									23		
Sample B		76,5	1,7	2,2	23							0		CRV	78,17	0,92	9%	71,1	85,3	23	23	100%	
(1) Biuret		76,5	1,7	2,2	23							0									23		
(10) Albumin					20							20	20	100%							0		
Samples and groups	[g/L]																						
Sample A		35,9	1,5	4,1	20	CVP	35,9	0,37	12%	31,5	40,3	20	20	100%							0		
(1) BCG		35,9	1,5	4,1	20							20											
Sample B		48,6	1,3	2,7	20	CVP	48,9	0,36	12%	43	54,8	20	20	100%							0		

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of groups n = 5

EQA round: AKS3/17 - Basic Clinical Chemistry - Serum

Dead line: 28.07.2017

Test	[unit]	Comparability					Traceability																	
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}		
(10) Albumin					20							20	20	100%							0			
Samples and groups	[g/L]																							
Sample B		48,6	1,3	2,7	20	CVP	48,9	0,36	12%	43	54,8	20	20	100%							0			
(1) BCG		48,6	1,3	2,7	20	0						20												
(11) Osmolality					10							10	10	100%							0			
Samples and groups	[mmol/kg]																							
Sample A		309	5,3	1,7	10	CVP	310	2,2	5%	294	326	10	10	100%							0			
(1) Osmometer		309	5,3	1,7	10	0						10												
Sample B		312	4,8	1,5	10	CVP	312	2,4	5%	296	328	10	10	100%							0			
(1) Osmometer		312	4,8	1,5	10	0						10												
(12) Lactate					14							14	14	100%							0			
Samples and groups	[mmol/L]																							
Sample A		3,40	0,13	3,8	14	CVP	3,39	0,049	15%	2,88	3,9	14	14	100%							0			
(3) Photometric enzyme method		3,39	0,14	4,0	10	0						10												
Other					4	0						4												
Sample B		5,00	0,21	4,3	14	CVP	4,95	0,073	15%	4,2	5,7	14	14	100%							0			
(3) Photometric enzyme method		4,99	0,24	4,7	10	0						10												
Other					4	0						4												
(13) Bilirubin total					22							0									22	22	100%	
Samples and groups	[µmol/L]																							
Sample A		55,8	4,2	7,6	22							0	CRV	57,2	1,3	21%	45,1	69,3			22	22	100%	
(2) DCA, DPD		56,2	3,9	7,0	21	0															21			
Other					1	0															1			
Sample B		72,3	5,2	7,2	22							0	CRV	76	1,7	21%	60	92			22	22	100%	
(2) DCA, DPD		72,7	4,9	6,8	21	0															21			
Other					1	0															1			
(15) Cholesterol					20							0									20	19	95%	
Samples and groups	[mmol/L]																							
Sample A		3,51	0,10	3,0	20							0									20	20	100%	
(1) Enzyme CHOD-PAP		3,51	0,10	3,0	20	0							CRV	3,685	0,037	9%	3,35	4,02			20			
Sample B		4,62	0,17	3,6	20							0									20	19	95%	
(1) Enzyme CHOD-PAP		4,62	0,17	3,6	20	0							CRV	4,793	0,048	9%	4,36	5,23			20			
(16) Glucose					22							0									22	22	100%	
Samples and groups	[mmol/L]																							
Sample A		8,83	0,20	2,3	22							0	CRV	8,925	0,089	9%	8,12	9,73			22	22	100%	
(1) GOD photometry		8,82	0,09	1,1	7	0															7			
(3) Method with hexokinase		8,88	0,27	3,0	15	0															15			
Sample B		11,8	0,26	2,2	22							0	CRV	12,04	0,12	9%	10,9	13,2			22	22	100%	
(1) GOD photometry		11,9	0,19	1,6	7	0															7			
(3) Method with hexokinase		11,8	0,29	2,5	15	0															15			

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of groups n = 5

EQA round: AKS3/17 - Basic Clinical Chemistry - Serum

Dead line: 28.07.2017

Test	[unit]	Comparability					Traceability													
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}						
(17) Uric acid					21						0			21	20	95%				
Samples and groups	[µmol/L]																			
Sample A		252	10	4,0	21						0	CRV	256,2	2,6	12%	225	287	21	21	100%
(2) Enzyme-photomet. m.		252	10	4,0	21	0												21		
Sample B		313	12	3,8	21						0	CRV	316,5	3,2	12%	278	355	21	20	95%
(2) Enzyme-photomet. m.		313	12	3,8	21	0												21		
(18) Urea					22						0							22	22	100%
Samples and groups	[mmol/L]																			
Sample A		25,4	0,90	3,5	22						0	CRV	26,26	0,26	15%	22,3	30,2	22	22	100%
(1) UV enzymatic m.(GMD)		25,4	0,90	3,5	22	0												22		
Sample B		9,98	0,34	3,4	22						0	CRV	10,09	0,100	15%	8,57	11,7	22	22	100%
(1) UV enzymatic m.(GMD)		9,98	0,34	3,4	22	0												22		
(19) Creatinine					22						0							22	22	100%
Samples and groups	[µmol/L]																			
Sample A		500	15	3,0	22						0	CRV	511,5	5,1	15%	434	589	22	22	100%
(2) Jaffé without depro. (with corr.)		491	11	2,2	10	0												10		
(3) Enzyme		508	13	2,5	11	0												11		
Other					1	0												1		
Sample B		148	7,6	5,2	22						0	CRV	151,1	1,5	15%	128	174	22	22	100%
(2) Jaffé without depro. (with corr.)		147	13	8,9	10	0												10		
(3) Enzyme		148	5,3	3,6	11	0												11		
Other					1	0												1		
(20) Triglycerides					20						0							20	20	100%
Samples and groups	[mmol/L]																			
Sample A		1,09	0,05	4,8	20						0	CRV	1,065	0,011	15%	0,905	1,23	20	20	100%
(1) GPO-PAP		1,09	0,05	4,8	20	0												20		
Sample B		1,95	0,05	3,0	20						0	CRV	2,03	0,020	15%	1,72	2,34	20	20	100%
(1) GPO-PAP		1,95	0,05	3,0	20	0												20		
(21) ALP					21						7	7	100%					14	13	93%
Samples and groups	[µkat/L]																			
Sample A		3,30	0,49	15	21						7	7	100%					14	14	100%
(3) IFCC method		3,47	0,52	15	14	0								CRV	3,621	0,088	24%	2,75	4,49	14
(3) IFCC method; (60) Roche		2,99	0,19	6,4	7	0	CVPG	2,93	0,055	18%	2,4	3,46								
Sample B		6,35	1,2	18	21						7	7	100%					14	13	93%
(3) IFCC method		6,78	1,2	18	14	0								CRV	6,886	0,16	24%	5,23	8,54	14
(3) IFCC method; (60) Roche		5,51	0,22	3,9	7	0	CVPG	5,49	0,092	18%	4,5	6,48								
(22) alpha-amylase					22						0							22	22	100%
Samples and groups	[µkat/L]																			
Sample A		5,14	0,21	4,1	22						0							22	22	100%
(1) IFCC method		5,14	0,21	4,1	22	0								CRV	5,246	0,14	15%	4,45	6,04	22
Sample B		3,77	0,16	4,4	22						0							22	22	100%
(1) IFCC method		3,77	0,16	4,4	22	0								CRV	3,811	0,11	15%	3,23	4,39	22

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of groups n = 5

EQA round: AKS3/17 - Basic Clinical Chemistry - Serum

Dead line: 28.07.2017

Test	[unit]	Comparability					Traceability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(23) AST					22							22	20	91%
Samples and groups	[µkat/L]													
Sample A		1,71	0,10	6,0	22							22	20	91%
(1) IFCC method		1,71	0,10	6,0	22	0			CRV	1,804	0,040	15%	1,53	2,08
Sample B		2,43	0,18	7,3	22							22	20	91%
(1) IFCC method		2,43	0,18	7,3	22	0			CRV	2,474	0,060	15%	2,1	2,85
(24) ALT					23							23	20	87%
Samples and groups	[µkat/L]													
Sample A		3,95	0,17	4,2	23							23	21	91%
(1) IFCC method		3,95	0,17	4,2	23	0			CRV	4,094	0,090	15%	3,47	4,71
Sample B		2,31	0,12	5,1	23							23	21	91%
(1) IFCC method		2,31	0,12	5,1	23	0			CRV	2,355	0,052	15%	2	2,71
(26) CK					21							21	20	95%
Samples and groups	[µkat/L]													
Sample A		6,46	0,39	6,0	21							21	20	95%
(1) IFCC method		6,46	0,39	6,0	21	0			CRV	7,155	0,18	20%	5,72	8,59
Sample B		8,20	0,47	5,7	21							21	21	100%
(1) IFCC method		8,20	0,47	5,7	21	0			CRV	8,705	0,21	20%	6,96	10,5
(27) gamma-GT					21							21	21	100%
Samples and groups	[µkat/L]													
Sample A		2,81	0,16	5,5	21							21	21	100%
(1) IFCC method		2,83	0,15	5,1	20	0			CRV	2,877	0,072	15%	2,44	3,31
Other					1	0								1
Sample B		3,11	0,18	5,6	21							21	21	100%
(1) IFCC method		3,13	0,16	5,1	20	0			CRV	3,181	0,078	15%	2,7	3,66
Other					1	0								1
(28) LD					20							20	19	95%
Samples and groups	[µkat/L]													
Sample A		3,70	0,16	4,3	20							20	19	95%
(3) IFCC method		3,70	0,16	4,3	20	0			CRV	3,829	0,085	18%	3,13	4,52
Sample B		5,14	0,25	4,8	20							20	19	95%
(3) IFCC method		5,14	0,25	4,8	20	0			CRV	5,039	0,11	18%	4,13	5,95
(29) Lipase					15						13	13	100%	0
Samples and groups	[µkat/L]													
Sample A		1,21	0,13	11	15						13	13	100%	0
(1) Photometry; (58) Beckman Coulter (Olympus)		1,34	0,00	0,00	5	0	CVPG	1,37	0,052	24%	1,04	1,7		5
(1) Photometry; (60) Roche		1,14	0,09	8,5	7	0	CVPG	1,15	0,044	24%	0,874	1,43		7
Other					3	0								1
														1x 1/12, 1x 1/85, 1x 1/178
Sample B		2,34	0,38	16	15						13	13	100%	0
(1) Photometry; (58) Beckman Coulter (Olympus)		2,66	0,03	1,1	5	0	CVPG	2,67	0,086	24%	2,02	3,32		5
(1) Photometry; (60) Roche		2,09	0,22	10	7	0	CVPG	2,1	0,093	24%	1,59	2,61		7

